Celator® Pharmaceuticals Receives FDA Fast Track Designation For CPX-351 For The Treatment Of Elderly Patients With Secondary Acute Myeloid Leukemia
January 20, 2015Celator® Pharmaceuticals receives Fast Track designation for their lead candidate CPX-351 by the FDA. This will expedite the development and review of the drug since it is intended to treat life-threatening secondary Acute Myeloid Leukemia (AML) in elder
More »
Tobira Therapeutics Doses First Subject in Phase 1 Clinical Trial of Cenicriviroc and Pioglitazone
January 20, 2015Tobira Therapeutics dosed the first subject in a Phase 1 safety study to evaluate cenicriviroc (CVC) and diabetes medication pioglitazone, which supports their larger CVC clinical program in non-alcoholic steatohepatitis, often associated with diabetes.
More »
First Patient Enrolled in EVoluSIon Clinical Study
January 19, 2015Zyga Technology enrolls the first patient in its EVoluSIon Study, a U.S. multicenter single-arm study that will include up to 50 patients, designed to evaluate fusion and pain reduction after use of the Zyga SImmetry Sacroiliac Joint Fusion System.
More »